Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 955 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Bayer Clear all
Completed Not applicable Interventional Results available

Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172

NCT01222351
View directory record Official record
Conditions
Late Onset Alzheimer Disease
Interventions
BAY 94-9172 (Florbetaben)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
65 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Not applicable Interventional Results available

Combination Gel and Vascular ND in Mild to Moderate Rosacea

NCT01631656
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid, Nd:Yag laser
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea

NCT00855595
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic acid (Finacea, BAY39-6251), Metronidazole (Metrogel), Doxycycline (Oracea)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
17
States / cities
Birmingham, Alabama • Denver, Colorado • West Palm Beach, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 16, 2026, 2:41 PM EDT
Terminated Phase 2 Interventional Results available

Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas

NCT01338857
View directory record Official record
Conditions
neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma
Interventions
Sorafenib (Nexavar)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

NCT02799602
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
58
States / cities
Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 16, 2026, 2:41 PM EDT
Terminated Phase 1 Interventional

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

NCT04267939
View directory record Official record
Conditions
Advanced Solid Tumors (Excluding Prostate Cancer), Ovarian Cancer
Interventions
Elimusertib (BAY1895344), Niraparib
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

18791 - Sun Protection Factor Assay

NCT02682628
View directory record Official record
Conditions
Sunscreening Agent
Interventions
Coppertone (BAY987517)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 16, 2026, 2:41 PM EDT
Withdrawn Phase 2 Interventional

Coronary Vasomotor Response After Riociguat Exposure

NCT01165931
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Riociguat (BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study

NCT00528112
View directory record Official record
Conditions
Contraception
Interventions
LCS12, LCS16
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
2,885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
57
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes

NCT00206622
View directory record Official record
Conditions
Hot Flashes
Interventions
Climara PRO (Estradiol / Levonorgestrel transdermal), Menostar (Estradiol transdermal), Placebo transdermal
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
45
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated May 29, 2009 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

18475 - Sun Protection Factor Assay

NCT02774252
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY987521
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 16, 2026, 2:41 PM EDT
Terminated Phase 2 Interventional

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

NCT00313482
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
Sargramostim, Docetaxel, Prednisone
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2012 · Synced Oct 16, 2026, 2:41 PM EDT
Terminated Phase 3 Interventional Results available

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

NCT02556203
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic Acid (ASA), Clopidogrel, Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
31
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

NCT00629837
View directory record Official record
Conditions
Hemophilia A
Interventions
Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980), Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Biological
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 60 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Davis, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

18841- Sun Protection Factor Assay

NCT02717351
View directory record Official record
Conditions
Sunscreening Agent
Interventions
Coppertone (BAY 987517)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics

NCT03655301
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Copanlisib (Aliqopa, BAY80-6946), Metformin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

NCT02106832
View directory record Official record
Conditions
Bronchiectasis
Interventions
Ciprofloxacin (BAYQ3939) dry powder for inhalation, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Peoria, Arizona • Fountain Valley, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 16, 2026, 2:41 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

NCT07723248
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
Coral Springs, Florida • Jeffersonville, Indiana • Holland, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Not applicable Interventional

Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo

NCT02661438
View directory record Official record
Conditions
Bronchiectasis, Pulmonary Disease, Chronic Obstructive
Interventions
Placebo to Ciprofloxacin DPI (BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Vero Beach, Florida • Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

NCT04126733
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Regorafenib (Stivarga, BAY73-4506), Nivolumab (Opdivo)
Drug · Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
15
States / cities
Duarte, California • Denver, Colorado • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 16, 2026, 2:41 PM EDT
Terminated Phase 2 Interventional

Exploratory Study for Allergy Relief Onset

NCT02722083
View directory record Official record
Conditions
Rhinitis, Allergic
Interventions
Chlorpheniramine maleate (BAY X002134), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

NCT01833520
View directory record Official record
Conditions
Sarcoma
Interventions
Ra-223 Dichloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 16, 2026, 2:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Essure Transvaginal Ultrasound (TVU) Study

NCT01327105
View directory record Official record
Conditions
Contraceptive Usage
Interventions
TVU
Device
Lead sponsor
Bayer
Industry
Eligibility
21 Years to 44 Years · Female only
Enrollment
547 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2023
U.S. locations
13
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 16, 2026, 2:41 PM EDT
Completed No phase listed Observational

Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma

NCT00876382
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Not listed
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Jonesboro, Arkansas • St. Petersburg, Florida • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 16, 2026, 2:41 PM EDT